Epizyme, Inc.
Clinical trials sponsored by Epizyme, Inc., explained in plain language.
Now part of
Ipsen S.A.
IPN
EURONEXT PARIS
Biopharmaceutical company developing epigenetic therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial Results expected Feb 2027 (estimated) 🚀 Make-or-break